RNAi technologies that make immune cells more effective in killing tumor cells
RNAitechnologies that make immune cells more effective in killing tumor cells
Who we are
We’re a clinical stage biotech co-founded by the Nobel scientist who discovered RNA interference.
Our Science
Our proprietary INTASYL technology is a platform for self-delivering RNAi immuno-oncology therapies.
Pipeline
Phio is focused on key initiatives for the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma.
Investors
Phio has brought on new leadership as it pivots from discovery to development.